Abstract
Background Invasive pneumococcal disease (IPD) declined during the COVID-19 pandemic. Previous studies hypothesized that this was due to reduced pneumococcal transmission resulting from non-pharmacological interventions. We used multiple ongoing cohort surveillance projects in children <5 years to test this hypothesis.
Methods The first SARS-CoV-2 cases were detected in February-2020, resulting in a full lockdown, followed by several partial restrictions. Data from ongoing surveillance projects captured the incidence dynamics of community-acquired alveolar pneumonia (CAAP), non-alveolar lower respiratory infections necessitating chest X-rays (NA-LRI), nasopharyngeal pneumococcal carriage in non-respiratory visits, nasopharyngeal respiratory virus detection (by PCR), and nationwide invasive pneumococcal disease (IPD). Monthly rates (January-2020 through February-2021 vs. mean monthly rates 2016-2019 [expected rates]) adjusted for age and ethnicity, were compared.
Findings CAAP and bacteremic pneumococcal pneumonia were strongly reduced (incidence rate ratios, [IRRs] 0η07 and 0η19, respectively); NA-LRI and non-pneumonia IPD were also reduced, with a lesser magnitude (IRRs, 0η46 and 0η42, respectively). In contrast, pneumococcal carriage prevalence was only slightly reduced and density of colonization and pneumococcal serotype distributions were similar to previous years. The pneumococcus-associated disease decline was temporally associated with a full suppression of RSV, influenza viruses, and hMPV, often implicated as co-pathogens with pneumococcus. In contrast, adenovirus, rhinovirus, and parainfluenza activities were within or above expected levels.
Interpretation Reductions in pneumococcal and pneumococcus-associated diseases occurring during the COVID-19 pandemic were not predominantly related to reduced pneumococcal transmission and carriage but were strongly associated with the complete disappearance of specific respiratory viruses.
Funding Partially funded by Pfizer, Inc.
Competing Interest Statement
Shalom Ben-Shimol has received grant/research support, honorarium for scientific consultancy, speaker bureau and participation in advisory committees from Pfizer Inc.; honorarium for scientific consultancy, speaker bureau and participation in advisory committees from MSD; speaker bureau from GlaxoSmithkline. David Greenberg has received honorarium for scientific consultancy and speaker bureau from Pfizer, Inc.; grant/research support, honorarium for scientific consultancy a speaker bureau from MSD; honorarium for scientific consultancy and speaker bureau from GlaxoSmithkline. Daniel M. Weinberger has received consulting fees from Pfizer, Merck, and Affinivax for work unrelated to this manuscript and is Principal Investigator on research grants from Pfizer and Merck to Yale University. Ron Dagan has received grant/research support, honorarium for scientific consultancy, speaker bureau and participation in advisory committees from Pfizer Inc.; grant/research support, honorarium for scientific consultancy, speaker bureau and participation in advisory committees from MSD; grant/research support from MedImmune. The other authors have no conflicts of interest to declare
Funding Statement
Supported in part by a grant from Pfizer, Inc. Pfizer Inc. was not engaged in the preparation of the manuscript in any way and was not given the opportunity to review the manuscript before its submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Soroka University Medical Center Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We have included all the available data in the manuscript and supplementary file
